Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents-Reference-Cited by-同舟云学术

Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents

Published:2022-09-12 Issue:17 Volume:6 Page:5227-5231
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Johnson Isla M.¹,Bezerra Evandro D.¹^ORCID,Farrukh Faiqa¹,McCullough Kristen¹^ORCID,Al-Kali Aref¹,Alkhateeb Hassan B.¹,Begna Kebede¹^ORCID,Litzow Mark R.¹^ORCID,Hogan William J.¹,Shah Mithun Vinod¹^ORCID,Patnaik Mrinal M.¹^ORCID,Tefferi Ayalew¹,Gangat Naseema¹^ORCID

Affiliation:

1. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/6/17/5227/1919358/advancesadv2022007333.pdf

Reference13 articles.

1. Azacitidine and venetoclax in previously untreated acute myeloid leukemia;DiNardo;N Engl J Med.,2020

2. Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: case reports and disproportionality analyses in Vigibase;Perino;Br J Clin Pharmacol.,2020

3. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia;Raza;Cancer.,2008